drugset / Trial / NCT06315920

Analgesic Effect of Parecoxib Versus Morphine in SCD Patients Presenting to the Emergency Department

NCT06315920

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Introduction: This study focuses on the treatment of painful crises in Sickle Cell Disease (SCD) patients using Paracoxib, a non-opioid, compared to Morphine. It addresses the need for alternative medications that reduce opioid dependency while providing effective analgesia. Objectives: Primary: Evaluate the analgesic effect of Paracoxib versus Morphine in SCD vaso-occlusive crises. Secondary: Reduce opioid use/dependence, decrease the length of hospital stays, and monitor side effects related to Paracoxib. Methodology: A double-blinded randomized controlled trial, conducted in a tertiary care emergency department. The study includes adult SCD patients with moderate to severe crises, excluding non-VOC pain, certain medications, and specific medical conditions. The sample size is 226 patients, split equally into two groups. Intervention: Patients receive either Morphine or Paracoxib, with periodic assessment of vital signs and pain. Additional Morphine is administered if required. Data collection and analysis are meticulously planned. Expected Outcomes: Improvement in SCD pain management, reduction in opioid usage, and potential benefits in terms of hospital stays and patient satisfaction.

Timeline

Start
2026-05-01
Primary completion
2028-05-01
Completion
2028-07-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Morphine Other / unclassified 5 mg Intravenous
Subject Parecoxib Small molecule 40 mg Intravenous

Indications